Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-Blind Trial of Artemisinin to Reduce The Symptoms of Schizophrenia

NCT00753506 is registered in ClinicalTrials.gov with Sheppard Pratt Health System as lead sponsor.

NCT NCT00753506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00753506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-Blind Trial of Artemisinin to Reduce The Symptoms of Schizophrenia
Lead sponsor
Sheppard Pratt Health System
Phase
Not applicable
Overall status
Completed
Start date
August 31, 2008
Completion date
May 31, 2010
Enrollment
66 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia